Selection Guide,significantly reduced the quality of liposome membrane

The field of antimicrobial research is constantly seeking novel and effective strategies to combat the growing threat of antibiotic resistance. Antimicrobial peptides (AMPs), a vital component of the innate immune system, have emerged as promising candidates due to their broad-spectrum activity and unique mechanisms of action. However, their therapeutic efficacy can be significantly influenced by their interaction with liposomes, which are increasingly being explored as delivery vehicles. A critical aspect of this interaction is aggregation, a complex process that can profoundly impact both the antimicrobial properties of the peptides and the integrity of the liposomes.

Research has consistently demonstrated that aggregation strongly increases peptide selectivity in the context of membrane interactions. For instance, studies on anticancer peptides like killerFLIP have shown that aggregation leads to enhanced selectivity, by reducing the effective peptide concentration that interacts with the membrane. This phenomenon is particularly relevant for cationic antimicrobial peptides (CAMPs), which offer a promising strategy to counteract bacterial resistance primarily through their membrane-targeting activity. The aggregation of these peptides can lead to more efficient membrane leakage and destabilization of the bacterial cell wall, membrane, and even cytosolic proteins. In some cases, aggregation of antimicrobial peptides (AMPs) has been shown to enhance their efficacy.

The relationship between peptide structure and antimicrobial activity is intricate, and aggregation plays a pivotal role. While some studies indicate that aggregation can mediate efficient membrane leakage, it can also lead to negligible membrane fusion and liposome aggregation. This suggests a delicate balance where controlled aggregation can be beneficial, but excessive or uncontrolled aggregation might lead to undesirable outcomes. The aggregation behavior of peptides in water is influenced by various factors including peptide concentration, temperature, pH, ionic strength, and the presence of other molecules.

Liposomes, as model biological membranes, are frequently used to study these interactions. The composition of these liposomes is crucial. For example, DOPE/DOPG liposomes have been utilized in experiments to understand nanoparticle-induced liposome aggregation. The dynamics of liposome-antimicrobial peptide interaction are also influenced by factors like lipid-A-dependent and cholesterol-dependent dynamics, highlighting the complex interplay between the peptide and the lipid bilayer. Furthermore, the effect of liposome surface charge and peptide side-chain interactions can dictate how antimicrobial peptides interact with and potentially disrupt the liposome membrane. Studies have shown that certain antimicrobial peptides can significantly reduce the quality of the liposome membrane and increase its viscoelasticity.

Liposomes can also be engineered to enhance the delivery and efficacy of antimicrobial peptides. Liposome encapsulation is a strategy that can protect the antimicrobial activity of the peptides from degradation by proteolytic enzymes. Dual coating of liposomes as encapsulating matrix of antimicrobial peptides has been explored to improve their stability and targeted delivery. Moreover, peptide-decorated liposomes are being developed to enhance fungal targeting, as they can improve antifungal drug solubility and delivery while reducing toxicity by enhancing fungal cell interaction. Bio-inspired peptide-conjugated liposomes are also being designed for enhanced antibacterial efficacy.

The aggregation process itself is described as a complex and heterogenous process for peptides. The trigger for peptide aggregation is often peptide specific. For instance, the $\beta$-sheet H-bonding interaction between peptide backbones can prompt the axial aggregation of lipidated peptides. Molecular modeling results suggest that aggregation of N-lipidated AMPs may impart greater structural stability to the peptides in solution. Conversely, some neutral peptides can facilitate the aggregation of cationic antimicrobial peptides.

The potential for liposomes to induce the aggregation of certain peptides, such as the A$\beta$ peptide, has also been investigated, demonstrating that liposomes, as a model of biological membranes, can influence peptide aggregation. Various antimicrobial peptides have been shown to cause liposomes to aggregate, fuse, or leak, with these processes being closely related to the phases of the liposomes. The modification of conventional liposomes for targeted delivery can involve liposome fusion with the cell membrane, a process where certain peptides improve cell internalization for effective intracellular antimicrobial delivery.

In summary, the interplay between antimicrobial peptides and liposomes is a multifaceted area of research. Understanding the mechanisms and consequences of aggregation is paramount for developing effective liposomal formulations of antimicrobial peptides. Whether it enhances selectivity and efficacy or leads to membrane destabilization and leakage, aggregation is a key determinant of the therapeutic potential of these advanced antimicrobial strategies. Researchers continue to explore various liposomal formulations, including anionic liposome formulation for oral delivery of thuricin, and the encapsulation of antimicrobial peptides within these structures, aiming to harness the power of aggregation for improved antimicrobial outcomes.